255 related articles for article (PubMed ID: 12811365)
21. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
Tachibana-Iimori R; Tabara Y; Kusuhara H; Kohara K; Kawamoto R; Nakura J; Tokunaga K; Kondo I; Sugiyama Y; Miki T
Drug Metab Pharmacokinet; 2004 Oct; 19(5):375-80. PubMed ID: 15548849
[TBL] [Abstract][Full Text] [Related]
22. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.
Zaher H; Meyer zu Schwabedissen HE; Tirona RG; Cox ML; Obert LA; Agrawal N; Palandra J; Stock JL; Kim RB; Ware JA
Mol Pharmacol; 2008 Aug; 74(2):320-9. PubMed ID: 18413659
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Kameyama Y; Yamashita K; Kobayashi K; Hosokawa M; Chiba K
Pharmacogenet Genomics; 2005 Jul; 15(7):513-22. PubMed ID: 15970799
[TBL] [Abstract][Full Text] [Related]
24. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.
Morimoto K; Oishi T; Ueda S; Ueda M; Hosokawa M; Chiba K
Drug Metab Pharmacokinet; 2004 Dec; 19(6):453-5. PubMed ID: 15681900
[TBL] [Abstract][Full Text] [Related]
25. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects.
Koitabashi Y; Kumai T; Matsumoto N; Watanabe M; Sekine S; Yanagida Y; Kobayashi S
Life Sci; 2006 May; 78(24):2852-9. PubMed ID: 16412477
[TBL] [Abstract][Full Text] [Related]
26. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.
Becquemont L; Neuvonen M; Verstuyft C; Jaillon P; Letierce A; Neuvonen PJ; Funck-Brentano C
Clin Pharmacol Ther; 2007 May; 81(5):679-84. PubMed ID: 17301736
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).
Iwai M; Suzuki H; Ieiri I; Otsubo K; Sugiyama Y
Pharmacogenetics; 2004 Nov; 14(11):749-57. PubMed ID: 15564882
[TBL] [Abstract][Full Text] [Related]
28. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
30. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
Nassif A; Jia J; Keiser M; Oswald S; Modess C; Nagel S; Weitschies W; Hosten N; Siegmund W; Kühn JP
Radiology; 2012 Sep; 264(3):741-50. PubMed ID: 22771883
[TBL] [Abstract][Full Text] [Related]
31. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
Hsiang B; Zhu Y; Wang Z; Wu Y; Sasseville V; Yang WP; Kirchgessner TG
J Biol Chem; 1999 Dec; 274(52):37161-8. PubMed ID: 10601278
[TBL] [Abstract][Full Text] [Related]
32. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
33. OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.
Iusuf D; Ludwig M; Elbatsh A; van Esch A; van de Steeg E; Wagenaar E; van der Valk M; Lin F; van Tellingen O; Schinkel AH
Mol Cancer Ther; 2014 Feb; 13(2):492-503. PubMed ID: 24194565
[TBL] [Abstract][Full Text] [Related]
34. Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling.
Mao J; Doshi U; Wright M; Hop CECA; Li AP; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):251-258. PubMed ID: 29388346
[TBL] [Abstract][Full Text] [Related]
35. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics.
Erdman AR; Mangravite LM; Urban TJ; Lagpacan LL; Castro RA; de la Cruz M; Chan W; Huang CC; Johns SJ; Kawamoto M; Stryke D; Taylor TR; Carlson EJ; Ferrin TE; Brett CM; Burchard EG; Giacomini KM
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F905-12. PubMed ID: 16291576
[TBL] [Abstract][Full Text] [Related]
36. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Kindla J; Müller F; Mieth M; Fromm MF; König J
Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
[TBL] [Abstract][Full Text] [Related]
37. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
39. Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.
Wagner JB; Ruggiero M; Leeder JS; Hagenbuch B
Drug Metab Dispos; 2020 Nov; 48(11):1192-1198. PubMed ID: 32892153
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
Taguchi T; Masuo Y; Kogi T; Nakamichi N; Kato Y
J Pharm Sci; 2016 Jul; 105(7):2231-9. PubMed ID: 27290622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
